Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk

Atherosclerosis and atherosclerotic-related cardiovascular diseases (ASCVD) are characterized by high serum levels of low-density lipoprotein cholesterol (LDL-C) that can promote the generation of reactive oxygen species (ROS). To answer the need for better LDL-C control in individuals at high and v...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Alessia Silla, Federica Fogacci, Angela Punzo, Silvana Hrelia, Patrizia Simoni, Cristiana Caliceti, Arrigo F. G. Cicero
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2023-02-01
Edice:	Antioxidants
Témata:	Evolocumab PCSK9 inhibitor lipid-lowering treatment PBMC<sub>S</sub> H<sub>2</sub>O<sub>2</sub> chemiluminescence
On-line přístup:	https://www.mdpi.com/2076-3921/12/3/578
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!